{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:42:42Z","timestamp":1792590162776,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000950","name":"Alcon Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100000950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Minimally invasive glaucoma surgery (MIGS) has the potential to become standard of care for patients with primary open angle glaucoma (POAG), whether combined with cataract surgery (CS) or as a standalone procedure. This study provides evidence of cost-effectiveness for Hydrus Microstent for both indications in UK healthcare settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort Markov model simulated the natural history of POAG to assess costs and quality-adjusted life years (QALYs) over a 15-year horizon, comparing Hydrus Microstent + CS with CS alone, and Hydrus Microstent to iStent standalone. Patient progression across glaucoma severity health states was modelled using a rate of progression (RoP) derived from 5-year visual field loss data in HORIZON trial (for mild to moderate POAG) and by trial-based annual number of medications from COMPARE trial (for moderate POAG), respectively. Conducted from the public healthcare payer perspective, model inputs were derived from UK publicly available sources and\/or publications. Both deterministic and probabilistic analyses (PA) were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>When compared with CS alone, Hydrus + CS was estimated to generate 0.334 more QALYs but \u00a3604 higher costs over the 15-year time horizon. When comparing Hydrus to iStent, Hydrus had \u00a3534 in projected savings and generated 0.068 more QALYs. The PA showed that the probability of Hydrus + CS being cost-effective compared to CS alone is 87.6%, and about 71.5% when compared to iStent. The results were consistent across scenario analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hydrus implantation is a cost-effective strategy both in combination with CS (for mild-to-moderate POAG) and as a standalone procedure (for moderate POAG) in UK healthcare settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04970-8","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:13:45Z","timestamp":1792584825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hydrus microstent combined with cataract surgery or used alone: cost-utility analysis for UK"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-5005","authenticated-orcid":false,"given":"Gus","family":"Gazzard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3091-911X","authenticated-orcid":false,"given":"Anthony","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiqul","family":"Rather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-4609","authenticated-orcid":false,"given":"Sergey","family":"Muratov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"4970_CR1","doi-asserted-by":"publisher","first-page":"j3889","DOI":"10.1136\/bmj.j3889","volume":"358","author":"MPY Chan","year":"2017","unstructured":"Chan MPY, Broadway DC, Khawaja AP, Yip JLY, Garway-Heath DF, Burr JM, et al. Glaucoma and intraocular pressure in EPIC-Norfolk Eye Study: cross sectional study. BMJ (Clin Res ed). 2017;358:j3889.","journal-title":"BMJ (Clin Res ed)"},{"key":"4970_CR2","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","volume":"393","author":"G Gazzard","year":"2019","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet (Lond, Engl). 2019;393:1505\u201316.","journal-title":"Lancet (Lond, Engl)"},{"key":"4970_CR3","unstructured":"Centre for Ageing Better. The State of Ageing in 2023 2023 [Available from: https:\/\/ageing-better.org.uk\/sites\/default\/files\/2023-12\/The-State-of-Ageing-interactive-summary-2023-4.pdf."},{"key":"4970_CR4","unstructured":"Office of National Statistics. CT21_0003 - Age time series Census, 1981 to 2021 [Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/adhocs\/14813ct210003agetimeseriescensus1981to2021."},{"key":"4970_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/bjophthalmol-2012-302525","volume":"97","author":"MQ Rahman","year":"2013","unstructured":"Rahman MQ, Beard SM, Discombe R, Sharma R, Montgomery DM. Direct healthcare costs of glaucoma treatment. Br J Ophthalmol. 2013;97:720\u20134.","journal-title":"Br J Ophthalmol"},{"key":"4970_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41433-019-0656-z","volume":"34","author":"HDJ Hogg","year":"2020","unstructured":"Hogg HDJ, Connor A. 10-year trends in English primary care glaucoma prescribing. Eye (Lond). 2020;34:192\u20136.","journal-title":"Eye (Lond)"},{"key":"4970_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/13696998.2019.1646262","volume":"23","author":"P McGinley","year":"2020","unstructured":"McGinley P, Ansari E, Sandhu H, Dixon T. The cost burden of falls in people with glaucoma in National Health Service Hospital Trusts in the UK. J Med Econ. 2020;23:106\u201312.","journal-title":"J Med Econ"},{"key":"4970_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jcrs.2013.11.033","volume":"40","author":"M Grimfors","year":"2014","unstructured":"Grimfors M, Mollazadegan K, Lundstr\u00f6m M, Kugelberg M. Ocular comorbidity and self-assessed visual function after cataract surgery. J Cataract Refract Surg. 2014;40:1163\u20139.","journal-title":"J Cataract Refract Surg"},{"key":"4970_CR9","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.ophtha.2007.07.013","volume":"114","author":"Y Liu","year":"2007","unstructured":"Liu Y, Congdon NG, Fan H, Zhao X, Choi K, Lam DS. Ocular comorbidities among cataract-operated patients in rural China: the caring is hip Study of Cataract Outcomes and Uptake of Services (SCOUTS), report No. 3. Ophthalmology. 2007;114:e47\u2013e52.","journal-title":"Ophthalmology"},{"key":"4970_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/bjo.2008.149450","volume":"93","author":"N Murray","year":"2009","unstructured":"Murray N, Murray T. The burden of ocular comorbidity in cataract patients in West Africa. Br J Ophthalmol. 2009;93:124\u20135.","journal-title":"Br J Ophthalmol"},{"key":"4970_CR11","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(23)01289-8","volume":"402","author":"H Jayaram","year":"2023","unstructured":"Jayaram H, Kolko M, Friedman DS, Gazzard G. Glaucoma: now and beyond. Lancet (Lond, Engl). 2023;402:1788\u2013801.","journal-title":"Lancet (Lond, Engl)"},{"key":"4970_CR12","unstructured":"NICE. Glaucoma: diagnosis and management 2022 [Available from: https:\/\/www.nice.org.uk\/guidance\/ng81."},{"key":"4970_CR13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.ophtha.2015.06.022","volume":"122","author":"IIK Ahmed","year":"2015","unstructured":"Ahmed IIK. MIGS and the FDA: What\u2019s in a Name? Ophthalmology. 2015;122:1737\u20139.","journal-title":"Ophthalmology"},{"key":"4970_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.ophtha.2022.02.021","volume":"129","author":"IIK Ahmed","year":"2022","unstructured":"Ahmed IIK, De Francesco T, Rhee D, McCabe C, Flowers B, Gazzard G, et al. Long-term outcomes from the HORIZON randomized trial for a schlemm\u2019s canal microstent in combination cataract and glaucoma surgery. Ophthalmology. 2022;129:742\u201351.","journal-title":"Ophthalmology"},{"key":"4970_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ophtha.2018.05.012","volume":"126","author":"TW Samuelson","year":"2019","unstructured":"Samuelson TW, Chang DF, Marquis R, Flowers B, Lim KS, Ahmed IIK, et al. A schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. Ophthalmology. 2019;126:29\u201337.","journal-title":"Ophthalmology"},{"key":"4970_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ophtha.2019.03.006","volume":"126","author":"TW Samuelson","year":"2019","unstructured":"Samuelson TW, Sarkisian SR Jr., Lubeck DM, Stiles MC, Duh YJ, Romo EA, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126:811\u201321.","journal-title":"Ophthalmology"},{"key":"4970_CR17","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1136\/bjophthalmol-2021-319062","volume":"106","author":"LJ Holland","year":"2022","unstructured":"Holland LJ, Kirwan JF, Mercieca KJ. Effect of COVID-19 pandemic on glaucoma surgical practices in the UK. Br J Ophthalmol. 2022;106:1406\u201310.","journal-title":"Br J Ophthalmol"},{"key":"4970_CR18","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/s41433-025-03852-9","volume":"39","author":"AS Ansari","year":"2025","unstructured":"Ansari AS, Tatham AJ, Amerasinghe N, Gazzard G. Building consensus on MIGS: insights from a UKEGS survey. Eye (Lond). 2025;39:2107\u20139.","journal-title":"Eye (Lond)"},{"key":"4970_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ophtha.2019.04.034","volume":"127","author":"IIK Ahmed","year":"2020","unstructured":"Ahmed IIK, Fea A, Au L, Ang RE, Harasymowycz P, Jampel HD, et al. A prospective randomized trial comparing Hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: The COMPARE Study. Ophthalmology. 2020;127:52\u201361.","journal-title":"Ophthalmology"},{"key":"4970_CR20","first-page":"189","volume":"10","author":"GM Richter","year":"2016","unstructured":"Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016;10:189.","journal-title":"Clin Ophthalmol"},{"key":"4970_CR21","unstructured":"Examples of minimally invasive glaucoma surgery options Glaucoma UK [Available from: https:\/\/glaucoma.uk\/about-glaucoma\/treatments-surgery\/migs."},{"key":"4970_CR22","unstructured":"Ang RE. 2-year results from a prospective, multicenter, randomized comparison: Hydrus vs 2 iStents for standalone treatment of glaucoma. 33rd APACRS-30th SNEC; 2021; Singapore2021."},{"key":"4970_CR23","unstructured":"Poitras V, Wells C, Hutnik C, Klarenback S, So H, Tsoi B, et al. CADTH Optimal Use Reports. Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment. Ottawa (ON) a user\u2019s group panel, and from Medicus for writing articles or editorials and being on an expert panel on glaucoma management. The other authors declared no conflicts of interest relevant to this report.: Canadian Agency for Drugs and Technologies in Health Copyright \u00a92019 2019."},{"key":"4970_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ogla.2019.11.009","volume":"3","author":"IIK Ahmed","year":"2020","unstructured":"Ahmed IIK, Podbielski DW, Patel V, Falvey H, Murray J, Botteman M, et al. A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma. Ophthalmol Glaucoma. 2020;3:103\u201313.","journal-title":"Ophthalmol Glaucoma"},{"key":"4970_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ogla.2021.09.006","volume":"5","author":"S Sood","year":"2022","unstructured":"Sood S, Heilenbach N, Sanchez V, Glied S, Chen S, Al-Aswad LA. Cost-effectiveness analysis of minimally invasive trabecular meshwork stents with phacoemulsification. Ophthalmol Glaucoma. 2022;5:284\u201396.","journal-title":"Ophthalmol Glaucoma"},{"key":"4970_CR26","unstructured":"Cloutier L, D\u00e9sy F, Nshimyumukiza L. Ponts trab\u00e9culaires iStent\u00ae et iStent inject\u00ae pour la chirurgie micro-invasive du glaucome (CMIG). Institut national d\u2019excellence en sant\u00e9 et en services sociaux (INESSS); 2020."},{"key":"4970_CR27","doi-asserted-by":"publisher","first-page":"e0252130","DOI":"10.1371\/journal.pone.0252130","volume":"16","author":"K Nieland","year":"2021","unstructured":"Nieland K, Labb\u00e9 A, Schweitzer C, Gicquel G, Kleintjens J, Ostawal A, et al. A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France. PLoS One. 2021;16:e0252130.","journal-title":"PLoS One"},{"key":"4970_CR28","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1136\/bjo-2021-320887","volume":"107","author":"A Kernohan","year":"2023","unstructured":"Kernohan A, Homer T, Shabaninejad H, King AJ, Hudson J, Fernie G, et al. Cost-effectiveness of primary surgical versus primary medical management in the treatment of patients presenting with advanced glaucoma. Br J Ophthalmol. 2023;107:1452\u20137.","journal-title":"Br J Ophthalmol"},{"key":"4970_CR29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet (Lond, Engl). 2015;385:1295\u2013304.","journal-title":"Lancet (Lond, Engl)"},{"key":"4970_CR30","unstructured":"Hodapp E, Parrish RK, Anderson DR. Clinical decisions in glaucoma: Mosby Incorporated; 1993."},{"key":"4970_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ajo.2023.02.008","volume":"251","author":"G Montesano","year":"2023","unstructured":"Montesano G, Ometto G, Ahmed IIK, Ramulu PY, Chang DF, Crabb DP, et al. Five-Year Visual Field Outcomes of the HORIZON Trial. Am J Ophthalmol. 2023;251:143\u201355.","journal-title":"Am J Ophthalmol"},{"key":"4970_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/IJG.0000000000002453","volume":"33","author":"DJ Rhee","year":"2024","unstructured":"Rhee DJ, Sancheti H, Rothman AL, Herndon L, Brubaker JW, Patrianakos T, et al. Primary practice patterns for the initial management of open angle glaucoma. J glaucoma. 2024;33:671\u20138.","journal-title":"J glaucoma"},{"key":"4970_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1167\/iovs.13-13006","volume":"55","author":"LJ Saunders","year":"2014","unstructured":"Saunders LJ, Russell RA, Kirwan JF, McNaught AI, Crabb DP. Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime. Invest Ophthalmol Vis Sci. 2014;55:102\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4970_CR34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.5301\/EJO.2010.6112","volume":"21","author":"GC Rossi","year":"2011","unstructured":"Rossi GC, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21:410\u20134.","journal-title":"Eur J Ophthalmol"},{"key":"4970_CR35","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0161-6420(03)00462-7","volume":"110","author":"RM Schiffman","year":"2003","unstructured":"Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110:1412\u20139.","journal-title":"Ophthalmology"},{"key":"4970_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533\u201340.","journal-title":"Am J Ophthalmol"},{"key":"4970_CR37","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","volume":"118","author":"B Sleath","year":"2011","unstructured":"Sleath B, Blalock S, Covert D, Stone JL, Skinner AC, Muir K, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118:2398\u2013402.","journal-title":"Ophthalmology"},{"key":"4970_CR38","doi-asserted-by":"crossref","unstructured":"KOL Interview 2022.","DOI":"10.1007\/JHEP04(2022)002"},{"key":"4970_CR39","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/j.ophtha.2013.07.049","volume":"120","author":"JF Kirwan","year":"2013","unstructured":"Kirwan JF, Lockwood AJ, Shah P, Macleod A, Broadway DC, King AJ, et al. Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology. 2013;120:2532\u20139.","journal-title":"Ophthalmology"},{"key":"4970_CR40","unstructured":"NHS England. 2021\/22 National Cost Collection Data Publication 2024 [Available from: https:\/\/www.england.nhs.uk\/publication\/2021-22-national-cost-collection-data-publication\/."},{"key":"4970_CR41","unstructured":"Joint Formulary Committee. British National Formulary (online): London: BMJ and Pharmaceutical Press; 2023 [Available from: https:\/\/www.medicinescomplete.com."},{"key":"4970_CR42","unstructured":"UK Government. Drugs and pharmaceutical electronic Market Information Tool (eMIT) 2023 [Available from: https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit."},{"key":"4970_CR43","unstructured":"Centers for Medicare & Medicaid Services. Pharmacy Auditing and Dispensing Job Aid: Billing other dosage forms 2015 [updated December 2015. Available from: https:\/\/www.cms.gov\/Medicare-Medicaid-Coordination\/Fraud-Prevention\/Medicaid-Integrity-Education\/Downloads\/pharmacy-selfaudit-jobaid-billing-other.pdf."},{"key":"4970_CR44","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2165\/00019053-200523050-00005","volume":"23","author":"JE Tranmer","year":"2005","unstructured":"Tranmer JE. et al. Valuing patient and caregiver time: a review of the literature. PharmacoEconomics. 2005;23:449\u201359.","journal-title":"PharmacoEconomics"},{"key":"4970_CR45","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/archophthalmol.2009.96","volume":"127","author":"JL Stone","year":"2009","unstructured":"Stone JL, Robin AL, Novack GD, Covert DW, Cagle GD. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch Ophthalmol. 2009;127:732\u20136.","journal-title":"Arch Ophthalmol"},{"key":"4970_CR46","first-page":"670","volume":"148","author":"SJ Gedde","year":"2009","unstructured":"Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL, et al. Three-year follow-up of the tube versus trabeculectomy study. Am J Epidemiol. 2009;148:670\u201384.","journal-title":"Am J Epidemiol"},{"key":"4970_CR47","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418\u201323.","journal-title":"Br J Ophthalmol"},{"key":"4970_CR48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtos.2018.03.002","volume":"16","author":"ABC Wong","year":"2018","unstructured":"Wong ABC, Wang MTM, Liu K, Prime ZJ, Danesh-Meyer HV, Craig JP. Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye. Ocul Surf. 2018;16:289\u201393.","journal-title":"Ocul Surf"},{"key":"4970_CR49","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/13696998.2019.1572013","volume":"22","author":"V Patel","year":"2019","unstructured":"Patel V, Ahmed I, Podbielski D, Falvey H, Murray J, Goeree R. Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. J Med Econ. 2019;22:390\u2013401.","journal-title":"J Med Econ"},{"key":"4970_CR50","doi-asserted-by":"crossref","unstructured":"Ahmed IIK, Hussein I, Saheb H, Schlenker M, Schendel S, Muratov S, et al. Cost-effectiveness analysis of hydrus microstent for patients with mild to moderate primary open-angle glaucoma in Canada. Ophthalmol Glaucoma. 2015;8:302\u201311.","DOI":"10.1016\/j.ogla.2025.01.008"},{"key":"4970_CR51","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1136\/bjo-2023-323390","volume":"108","author":"H Shabaninejad","year":"2024","unstructured":"Shabaninejad H, Homer T, Kernohan A, King AJ, Burr J, Azuara-Blanco A, et al. Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model. Br J Ophthalmol. 2024;108:1210\u20135.","journal-title":"Br J Ophthalmol"},{"key":"4970_CR52","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295\u2013304.","journal-title":"Lancet"},{"key":"4970_CR53","unstructured":"Public Health Agency of Canada. Seniors\u2019 Falls in Canada: SECOND Report 2014 [Available from: https:\/\/www.phac-aspc.gc.ca\/seniors-aines\/publications\/public\/injury-blessure\/seniors_falls-chutes_aines\/assets\/pdf\/seniors_falls-chutes_aines-eng.pdf."},{"key":"4970_CR54","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ophtha.2009.06.063","volume":"117","author":"CM Patino","year":"2010","unstructured":"Patino CM, McKean-Cowdin R, Azen SP, Allison JC, Choudhury F, Varma R. Group LALES. Central and peripheral visual impairment and the risk of falls and falls with injury. Ophthalmology. 2010;117:199\u2013206.e1.","journal-title":"Ophthalmology"},{"key":"4970_CR55","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1167\/iovs.11-8794","volume":"53","author":"DD Zheng","year":"2012","unstructured":"Zheng DD, Christ SL, Lam BL, Arheart KL, Galor A, Lee DJ. Increased mortality risk among the visually impaired: the roles of mental well-being and preventive care practices. Investig Ophthalmol Vis Sci. 2012;53:2685\u201392.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4970_CR56","doi-asserted-by":"publisher","first-page":"A248","DOI":"10.1016\/S1098-3015(11)71888-5","volume":"13","author":"L Gerlier","year":"2010","unstructured":"Gerlier L, Lamotte M, Verboven Y. MA3 glaucoma disease progression states: establishing a direct, quantitative link between visual field defects and utility loss. Value Health. 2010;13:A248.","journal-title":"Value Health"},{"key":"4970_CR57","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2165\/11316830-000000000-00000","volume":"26","author":"T Mills","year":"2009","unstructured":"Mills T, Law SK, Walt J, Buchholz P, Hansen J. Quality of life in glaucoma and three other chronic diseases: a systematic literature review. Drugs aging. 2009;26:933\u201350.","journal-title":"Drugs aging"},{"key":"4970_CR58","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/injuryprev-2019-043184","volume":"26","author":"M Boyd","year":"2020","unstructured":"Boyd M, Kvizhinadze G, Kho A, Wilson G, Wilson N. Cataract surgery for falls prevention and improving vision: modelling the health gain, health system costs and cost-effectiveness in a high-income country. Inj Prev. 2020;26:302\u20139.","journal-title":"Inj Prev"},{"key":"4970_CR59","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/bjo.87.10.1201","volume":"87","author":"C Meads","year":"2003","unstructured":"Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol. 2003;87:1201\u20134.","journal-title":"Br J Ophthalmol"},{"key":"4970_CR60","unstructured":"Karen Jones, Helen Louise Ann Weatherly, Sarah Birch, Adriana Castelli, Martin John Chalkley, et al. Unit Costs of Health and Social Care 2023 Manual. Technical report. Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York), Kent, UK; 2024."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04970-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04970-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04970-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:03:45Z","timestamp":1792587825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04970-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":60,"alternative-id":["4970"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04970-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"COIs have been provided separately.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}